Clinical Trial Update: Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab with or without SBRT in clinical stage I–IIIA non-small cell lung cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2021-08-03